Search results for "HC"

showing 10 items of 2361 documents

Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape.

2019

Abstract Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to immune escape in malignant disease. As a prerequisite for developing immunologic approaches in cancer therapy, it is necessary to understand the ontogeny and the antigenic specificities of tumor-infiltrating Tregs. We addressed this question by using a λ-MYC transgenic mouse model of endogenously arising B-cell lymphoma, which mirrors key features of human Burkitt lymphoma. We show that Foxp3+ Tregs suppress antitumor responses in endogenous lymphoma. Ablation of Foxp3+ Tregs significantly delayed tumor development. The ratio of Treg to effector T cells was elevated in growing tumors, which could be …

0301 basic medicineGenetically modified mouseCancer ResearchLymphoma B-CellImmunologychemical and pharmacologic phenomenaMice TransgenicT-Lymphocytes RegulatoryEpitope03 medical and health sciences0302 clinical medicineAntigenCell Line TumorMHC class ImedicineAnimalsAntigensbiologyEffectorFOXP3hemic and immune systemsmedicine.diseaseLymphomaMice Inbred C57BL030104 developmental biologyTumor Escape030220 oncology & carcinogenesisCancer researchbiology.proteinTumor EscapePeptidesCancer immunology research
researchProduct

FANCD2 modulates the mitochondrial stress response to prevent common fragile site instability

2021

Common fragile sites (CFSs) are genomic regions frequently involved in cancer-associated rearrangements. Most CFSs lie within large genes, and their instability involves transcription- and replication-dependent mechanisms. Here, we uncover a role for the mitochondrial stress response pathway in the regulation of CFS stability in human cells. We show that FANCD2, a master regulator of CFS stability, dampens the activation of the mitochondrial stress response and prevents mitochondrial dysfunction. Genetic or pharmacological activation of mitochondrial stress signaling induces CFS gene expression and concomitant relocalization to CFSs of FANCD2. FANCD2 attenuates CFS gene transcription and pr…

0301 basic medicineGenome instabilitymusculoskeletal diseasesTranscription GeneticQH301-705.5RegulatorMedicine (miscellaneous)MitochondrionBiology[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyGeneral Biochemistry Genetics and Molecular BiologyOxidative PhosphorylationArticle03 medical and health sciences0302 clinical medicineTranscription (biology)Stress Physiologicalhemic and lymphatic diseasesGene expressionFANCD2HumansBiology (General)GeneUbiquitinsChromosomal fragile siteChromosome Fragile SitesChromosome FragilityFanconi Anemia Complementation Group D2 ProteinDNA damage and repair[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyHCT116 CellsCell biologyMitochondriaSettore BIO/18 - Genetica030104 developmental biologyGene Expression Regulation030220 oncology & carcinogenesisUnfolded Protein ResponseGeneral Agricultural and Biological SciencesDNA Damage
researchProduct

Viral resistance in HCV infection.

2018

The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review…

0301 basic medicineGenotypeTreatment outcomeDrug ResistanceDrug resistanceHepacivirusBiologyViral resistanceAntiviral AgentsVirological response03 medical and health sciences0302 clinical medicinePharmacotherapyDrug TherapyDrug Resistance Multiple ViralVirologyRibavirinmedicineHumansGenetic variabilityViralTreatment FailureChronicAntiviral Agents; Drug Therapy Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Drug Resistance Multiple ViralGenetic VariationHepatitis CHepatitis C Chronicmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis C030104 developmental biologyHCVImmunologyCombinationHcv treatment030211 gastroenterology & hepatologyDrug Therapy CombinationInterferonsMultipleCurrent opinion in virology
researchProduct

Special Issue “Mental Health Issues and Quality of Life in Older Individuals”

2021

There are numerous biological, psychological, and social factors that have a more or less prominent impact on the mental health of older adults [...]

0301 basic medicineGerontologyPaleontologyMental healthGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesEditorialn/a030104 developmental biology0302 clinical medicineQuality of life (healthcare)Space and Planetary Sciencelcsh:Qlcsh:SciencePsychology030217 neurology & neurosurgeryEcology Evolution Behavior and SystematicsLife
researchProduct

Immunization against Hepatitis B Surface Antigen (HBsAg) in a Cohort of Nursing Students Two Decades after Vaccination: Surprising Feedback

2019

Health-care students can be exposed to biological risks during university training. The persistence of long-term immunogenicity against hepatitis B virus (HBV) was analyzed in a cohort of nursing students two decades after primary vaccination. A total of 520 students were enrolled at the University of Palermo and were evaluated for levels of anti-HBsAg antibodies. The students were examined during the first year of their Degree Course and were checked two years later. All students with anti-HBsAg &lt

0301 basic medicineHBsAgeducationImmunologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeArticleHealthcare students03 medical and health sciences0302 clinical medicineNursingDrug DiscoverymedicinePharmacology (medical)030212 general & internal medicinework related biological riskHBV infectionHBV vaccinationPharmacologyHepatitis B virusbusiness.industrySettore MED/44 - Medicina Del LavoroImmunogenicityAntibody titerAnti-HBs titerVaccinationTiter030104 developmental biologyInfectious DiseasesImmunizationCohortHealthcare studentbusinessVaccines
researchProduct

First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity

2021

Remaining a major healthcare concern with nearly 29 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, 9 days prior to the pandemic declaration by WHO. Since then, more than 277,000 tests were carried out confirming a total of 1,464 cases of coronavirus disease 2019 (COVID-19) in the country as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing sequenci…

0301 basic medicineHCoV-19Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.disease_cause03 medical and health sciences0302 clinical medicinePandemicmedicineChinaOriginal ResearchCoronavirusGenetic diversitylcsh:R5-920SARS-CoV-2LatvianOutbreakCOVID-19General Medicinegenetic diversityVirologyLatvialanguage.human_language030104 developmental biologyGeography2019-nCoVlanguageMedicinenext-generation sequencingSevere acute respiratory syndrome coronaviruslcsh:Medicine (General)030217 neurology & neurosurgeryFrontiers in Medicine
researchProduct

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing

2019

The outcome of host-virus interactions is determined by a number of factors, some related to the virus, others to the host, such as environmental factors and genetic factors. Therefore, different individuals vary in their relative susceptibility to infections. Human cytomegalovirus (HCMV) is an important pathogen from a clinical point of view, as it causes significant morbidity and mortality in immunosuppressed or immunosenescent individuals, such as the transplanted patients and the elderly, respectively. It is, therefore, important to understand the mechanisms of virus infection control. In this review, we discuss recent advances in the immunobiology of HCMV-host interactions, with partic…

0301 basic medicineHuman cytomegalovirusAgingCellular immunityvirusesCytomegalovirusReviewlcsh:Chemistry0302 clinical medicineHLA AntigensGenotypeMedicineantibodieslcsh:QH301-705.5SpectroscopyimmunosenescenceImmunity CellularbiologyGeneral MedicineImmunosenescenceGMComputer Science ApplicationsKIRHLAantibodieCytomegalovirus InfectionsHost-Pathogen InteractionsAntibodyGenotypeNKCongenital cytomegalovirus infectionHuman leukocyte antigenelderlyCatalysisVirusInorganic Chemistry03 medical and health sciencesImmunogeneticsAnimalsHumansGenetic Predisposition to DiseasePhysical and Theoretical ChemistryMolecular BiologyHCMVSettore MED/04 - Patologia Generalebusiness.industryOrganic Chemistrymedicine.diseaseImmunity Humoral030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Immunologybiology.proteinbusiness030215 immunology
researchProduct

Mouse Model of Cytomegalovirus Disease and Immunotherapy in the Immunocompromised Host: Predictions for Medical Translation that Survived the “Test o…

2018

Human Cytomegalovirus (hCMV), which is the prototype member of the β-subfamily of the herpesvirus family, is a pathogen of high clinical relevance in recipients of hematopoietic cell transplantation (HCT). hCMV causes multiple-organ disease and interstitial pneumonia in particular upon infection during the immunocompromised period before hematopoietic reconstitution restores antiviral immunity. Clinical investigation of pathomechanisms and of strategies for an immune intervention aimed at restoring antiviral immunity earlier than by hematopoietic reconstitution are limited in patients to observational studies mainly because of ethical issues including the imperative medical indication …

0301 basic medicineHuman cytomegalovirusmouse modelmedicine.medical_treatmentViral pathogenesislcsh:QR1-502T lymphocytesCytomegalovirusMice TransgenicCD8 T cellsReviewDiseaseCD8-Positive T-Lymphocytesmedicine.disease_causelcsh:MicrobiologyImmunocompromised HostMice03 medical and health sciencesImmune systemVirologymedicineAnimalsHumansadoptive cell transferVirus classificationimmune evasioninterstitial pneumoniaimmune controlviral pathogenesisbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic reconstitutionCytomegalovirusImmunotherapyhematopoietic cell transplantation (HCT)medicine.diseaseAdoptive TransferTransplantationDisease Models Animalhumanized mice030104 developmental biologyInfectious DiseasesCytomegalovirus InfectionsImmunologyimmunotherapybusinessViruses
researchProduct

NKG2D stimulation of CD8(+) T cells during priming promotes their capacity to produce cytokines in response to viral infection in mice

2017

NKG2D is an activating receptor that is expressed on most cytotoxic cells of the immune system, including NK cells, γδ and CD8+ T cells. It is still a matter of debate whether and how NKG2D mediates priming of CD8+ T cells in vivo, due to a lack of studies where NKG2D is eliminated exclusively in these cells. Here we studied the impact of NKG2D on effector CD8+ T-cell formation. NKG2D-deficiency that is restricted to murine CD8+ T cells did not impair antigen-specific T-cell expansion following mCMV and LCMV infection, but reduced their capacity to produce cytokines. Upon infection, conventional dendritic cells induce NKG2D ligands, which drive cytokine production on CD8+ T cells via the Da…

0301 basic medicineImmunologyCytokines ; Dap10 ; Effector CD8+ T cells ; LCMV ; NKG2D ; mCMVchemical and pharmacologic phenomenaBiologyCD8+ T cellsNKG2D03 medical and health sciencesInterleukin 21Immunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellZAP70BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.hemic and immune systemsNKG2DNatural killer T cellmCMVbiological factors3. Good health030104 developmental biologyCostimulationPrimingImmunologyInterleukin 12CytokinesBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.European journal of immunology
researchProduct